Tirzepatide Once Weekly for the Treatment of Obesity
Тирзепатид один раз в неделю для лечения ожирения
2022-06-04
SCID: 54.1/pgfz6xra
Discuss with AI
GIP receptor agonistGLP-1 receptor agonistObesity treatmentRandomized controlled trialTirzepatide
Figures from the paper
Abstract (AI)
BACKGROUND: Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy and safety of tirzepatide, a novel glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptor agonist, in people with obesity are not known. METHODS: In this phase 3 double-blind, randomized, controlled trial, we assigned 2539 adults with a body-mass index (BMI; the weight in kilograms divided by the square of the height in meters) of 30 or more, or 27 or more and at least one weight-related complication, excluding diabetes, in a 1:1:1:1 ratio to receive once-weekly, subcutaneous tirzepatide (5 mg, 10 mg, or 15 mg) or placebo for 72 weeks, including a 20-week dose-escalation period. Coprimary end points were the percentage change in weight from baseline and a weight reduction of 5% or more. The treatment-regimen estimand assessed effects regardless of treatment discontinuation in the intention-to-treat population. RESULTS: At baseline, the mean body weight was 104.8 kg, the mean BMI was 38.0, and 94.5% of participants had a BMI of 30 or higher. The mean percentage change in weight at week 72 was -15.0% (95% confidence interval [CI], -15.9 to -14.2) with 5-mg weekly doses of tirzepatide, -19.5% (95% CI, -20.4 to -18.5) with 10-mg doses, and -20.9% (95% CI, -21.8 to -19.9) with 15-mg doses and -3.1% (95% CI, -4.3 to -1.9) with placebo (P<0.001 for all comparisons with placebo). The percentage of participants who had weight reduction of 5% or more was 85% (95% CI, 82 to 89), 89% (95% CI, 86 to 92), and 91% (95% CI, 88 to 94) with 5 mg, 10 mg, and 15 mg of tirzepatide, respectively, and 35% (95% CI, 30 to 39) with placebo; 50% (95% CI, 46 to 54) and 57% (95% CI, 53 to 61) of participants in the 10-mg and 15-mg groups had a reduction in body weight of 20% or more, as compared with 3% (95% CI, 1 to 5) in the placebo group (P<0.001 for all comparisons with placebo). Improvements in all prespecified cardiometabolic measures were observed with tirzepatide. The most common adverse events with tirzepatide were gastrointestinal, and most were mild to moderate in severity, occurring primarily during dose escalation. Adverse events caused treatment discontinuation in 4.3%, 7.1%, 6.2%, and 2.6% of participants receiving 5-mg, 10-mg, and 15-mg tirzepatide doses and placebo, respectively. CONCLUSIONS: In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly; SURMOUNT-1 ClinicalTrials.gov number, NCT04184622.).
Key Findings
1
All prespecified cardiometabolic measures improved with tirzepatide treatment, according to the abstract.
2
At least 5% weight loss occurred in 85%, 89%, and 91% of participants receiving 5, 10, and 15 mg tirzepatide, respectively, compared with 35% receiving placebo.
3
In a 72-week phase 3 trial of 2539 adults with obesity without diabetes, weekly tirzepatide produced substantially greater weight loss than placebo.
4
Mean weight change was -15.0%, -19.5%, and -20.9% with tirzepatide doses of 5, 10, and 15 mg, respectively, versus -3.1% with placebo.
5
Weight loss of at least 20% occurred in 50% of participants receiving 10 mg and 57% receiving 15 mg tirzepatide, versus 3% with placebo.
Research Object
Adults with obesity or overweight and weight-related complications, excluding diabetes, treated with once-weekly subcutaneous tirzepatide
Research Subject
The efficacy and safety of once-weekly tirzepatide for weight reduction and cardiometabolic improvement
Publication Details
Publication Date
2022-06-04
Journal
Publisher
ISSN
Cited by
4076
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest
References available in scid.ai1
Cited by20
Heart Disease and Stroke Statistics—2023 Update: A Report From the American Heart Association2023
2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension2023
2024 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association2024
Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)2022
Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity2024
Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity2023
Tirzepatide as Compared with Semaglutide for the Treatment of Obesity2025
Obesity Management in Adults2023
Tirzepatide for Obesity Treatment and Diabetes Prevention2024
Changes in lean body mass with glucagon‐like peptide ‐1‐based therapies and mitigation strategies2024
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines2025
GLP-1 single, dual, and triple receptor agonists for treating type 2 diabetes and obesity: a narrative review2024
2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines2025
Elective peri‐operative management of adults taking glucagon‐like peptide‐1 receptor agonists, glucose‐dependent insulinotropic peptide agonists and sodium‐glucose cotransporter‐2 inhibitors: a multidisciplinary consensus statement2025
Glucagon-like Receptor-1 agonists for obesity: Weight loss outcomes, tolerability, side effects, and risks2024
Efficacy and Safety of Tirzepatide in Adults With Type 1 Diabetes: A Proof of Concept Observational Study2024
Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)2024
What are community perspectives and experiences around GLP-1 receptor agonist medications for weight loss? A cross-sectional survey study in the UK2025
Tissue-specific activation of insulin signaling as a potential target for obesity-related metabolic disorders2024
Exploring Adults’ Experiences with Tirzepatide for Weight Loss: A Mixed-Methods Study2025